- Home
- DLX vs QURE Comparison
DLX vs QURE Comparison
Compare DLX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLX
- QURE
- Stock Information
- Founded
- DLX 1915
- QURE 1998
- Country
- DLX United States
- QURE Netherlands
- Employees
- DLX N/A
- QURE N/A
- Industry
- DLX Advertising
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- DLX Consumer Discretionary
- QURE Health Care
- Exchange
- DLX Nasdaq
- QURE Nasdaq
- Market Cap
- DLX 867.6M
- QURE 866.3M
- IPO Year
- DLX N/A
- QURE 2007
- Fundamental
- Price
- DLX $19.09
- QURE $69.92
- Analyst Decision
- DLX Strong Buy
- QURE Strong Buy
- Analyst Count
- DLX 1
- QURE 12
- Target Price
- DLX $23.00
- QURE $69.67
- AVG Volume (30 Days)
- DLX 224.6K
- QURE 2.6M
- Earning Date
- DLX 11-05-2025
- QURE 10-29-2025
- Dividend Yield
- DLX 6.29%
- QURE N/A
- EPS Growth
- DLX 49.73
- QURE N/A
- EPS
- DLX 1.28
- QURE N/A
- Revenue
- DLX $2,106,724,000.00
- QURE $14,337,000.00
- Revenue This Year
- DLX $0.20
- QURE N/A
- Revenue Next Year
- DLX $1.65
- QURE $229.18
- P/E Ratio
- DLX $14.87
- QURE N/A
- Revenue Growth
- DLX N/A
- QURE N/A
- 52 Week Low
- DLX $13.61
- QURE $5.35
- 52 Week High
- DLX $24.45
- QURE $71.50
- Technical
- Relative Strength Index (RSI)
- DLX 52.83
- QURE 71.14
- Support Level
- DLX $17.82
- QURE $58.05
- Resistance Level
- DLX $19.52
- QURE $71.50
- Average True Range (ATR)
- DLX 0.47
- QURE 3.89
- MACD
- DLX 0.08
- QURE -0.53
- Stochastic Oscillator
- DLX 74.71
- QURE 88.55
About DLX Deluxe Corporation
Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.